Table 1.
Main characteristics of the 3 in vivo selected studies on LCDG treatment in DD.
| Author Year [Ref.] | # Patients | F | Mean Age (Years) | Type of Diverticular Disease | Study Type | Arms | Single Center Yes/No |
Interventions | Follow-Up | Outcome Measure | Efficacy of Interventions |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tursi et al., 2006 [66] | 85 | 54 | 67 | Symptomatic uncomplicated DD in remission | Open RT | 3 | No | G1: 5-ASA 1.6 g/day G2: LCDG 8 × 109 CFU 15 days/month G3: LCDG 8 × 109 CFU 15 days/month + 5-ASA 1.6 g/day |
12 months | Remission of abdominal symptoms | Symptom free at 12 months: G1 76.7% (23/27) G2 76.7% (23/27) G3 96.7% (29/29) |
| Tursi et al., 2008 [67] | 75 | 42 | 65 | Symptomatic uncomplicated DD in remission | Open RT | 5 | Yes | G1: LCDG 16 × 109 CFU 10 days/month + 5-ASA 800 mg/day G2: LCDG 16 × 109 CFU 10 days/month + 5-ASA 1600 mg/day G3: 5-ASA 800 mg 10 days/month G4: 5-ASA 1600 mg 10 days/month G5: LCDG 16 × 109 CFU 10 days/month |
24 months | Remission of abdominal symptoms | Symptom free at 24 months: G1 93.7% (15/16) G2 92.3% (12/13) G3 84% (11/13) G4 80% (8/10) G5 86.9% (20/23) |
| Tursi et al., 2013 [68] | 210 | 101 | 62 | Symptomatic uncomplicated DD in remission | DB placebo-controlled RT | 4 | No | G1: LCDG 24 × 109 CFU 10 days/month + 5-ASA 1600 mg/day G2: LCDG placebo + 5-ASA 1600 mg/day for 10 days/month G3: LCDG 24 × 109 CFU 10 days/month + 5-ASA placebo G4: LCDG placebo + 5-ASA placebo |
12 months | Recurrence of abdominal symptoms | Recurrence of SUDD at 12 months: G1 0% (0/54) p > 0.01 vs. other arms G2 13.7% (7/51) G3 14.5% (8/55) G4 46.0% (23/50) |
Ref. = reference; # = number; F = female; DD = diverticular disease; DB = double blind; RT = randomized trial; G = group; ASA = mesalazine; LCDG = Lactobacillus.